Reviewer's report

Title: Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer

Version: 2 Date: 6 April 2004

Reviewer: Halfdan Sorbye

Reviewer's report:

Major Compulsory Revisions of the revised ms. (that the author must respond to before a decision on publication can be reached)

Most original criticisms have been met. This referee however strongly disagrees the way TTP is calculated, censoring all deaths not due to malignant death. This will give a false higher TTP when comparing to other studies. The authors should therefore specify more exactly both in methods and in results the number of patients censored in calculating TTP, and why the patient was censored. Alternatively an intention to treat TTP could be presented. The authors insist on presenting the data both in text and table/figure, which may not be a space problem in your journal.

What next?: Accept after minor essential revisions

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No

Declaration of competing interests:

Research funding has been received from Sanofi Synthelabo, Aventis Pharma and roche AS.